Crestor and Diphenhydramine Interaction: What Women Need to Know

The Short Answer: Can You Take Crestor and Diphenhydramine Together?

Rosuvastatin and diphenhydramine are not contraindicated together, and no major pharmacokinetic drug-drug interaction exists between them. You will not see a hard "do not combine" warning on either FDA label. What does exist is a clinically meaningful pharmacodynamic overlap, meaning the drugs act on the body in ways that compound each other's risks, particularly the sedation, dry mouth, urinary retention, and cognitive blunting that diphenhydramine causes.

For women specifically, those risks shift depending on your hormonal status, age, and whether you are pregnant, breastfeeding, or perimenopausal. This article covers each scenario directly.

How Rosuvastatin Works in the Female Body

Rosuvastatin is a high-potency HMG-CoA reductase inhibitor. It blocks cholesterol synthesis in the liver, lowering LDL-cholesterol by roughly 38-55% depending on dose, and it modestly raises HDL.

Metabolism: Why Rosuvastatin Is Different From Other Statins

Most statins are metabolized heavily by CYP3A4. Rosuvastatin is not. It undergoes limited CYP2C9 metabolism and is primarily a substrate of hepatic transporters OATP1B1 and OATP1B3. This matters for drug interactions because substances that inhibit CYP3A4 (like grapefruit) have almost no effect on rosuvastatin, but inhibitors of OATP transporters, such as cyclosporine and certain antiretrovirals, raise rosuvastatin levels sharply.

Diphenhydramine is not a meaningful inhibitor of OATP1B1, OATP1B3, or CYP2C9. It is primarily metabolized by CYP2D6 and CYP2C9 with some CYP3A4 involvement, but it does not significantly alter rosuvastatin plasma concentrations in either direction.

Sex-Specific Pharmacokinetics of Rosuvastatin

Women have modestly higher rosuvastatin plasma exposures than men. A pharmacokinetic study published in Clinical Pharmacokinetics found that female sex is associated with approximately 28% higher AUC for rosuvastatin compared to males, likely due to differences in body composition and transporter activity. The rosuvastatin prescribing information acknowledges that plasma concentrations are higher in women, which partly informs why myopathy risk is consistently higher in female patients.

How Diphenhydramine Works and Why It Matters for Women

Diphenhydramine blocks H1 histamine receptors, producing sedation and anti-allergic effects. It also blocks muscarinic acetylcholine receptors (anticholinergic), alpha-adrenergic receptors, and sodium channels. That broad receptor profile is the source of most of its problems.

The Anticholinergic Burden Problem

"Anticholinergic burden" is the cumulative effect of taking multiple drugs that block acetylcholine signaling. Diphenhydramine alone carries a high anticholinergic score. A 2019 cohort study in JAMA Internal Medicine followed 58,769 patients over 10 years and found that higher cumulative anticholinergic drug use was associated with a significantly increased dementia risk (adjusted OR 1.49 for the highest exposure category).

Women are prescribed anticholinergic drugs at higher rates than men and tend to have longer exposure periods. Post-menopausal women losing estrogen's neuroprotective effects may be more vulnerable to anticholinergic cognitive effects. The combination of a statin and diphenhydramine does not raise the anticholinergic burden of rosuvastatin itself (statins are not anticholinergic), but it does mean you are adding anticholinergic load on top of whatever else you are taking.

Sedation and Fall Risk at Midlife

Diphenhydramine produces meaningful next-day sedation. A study in the Journal of Clinical Pharmacology demonstrated that a single 50 mg dose of diphenhydramine significantly impaired psychomotor performance for up to 8 hours. Rosuvastatin does not add to sedation directly, but if you take other sedating medications (common at midlife: low-dose quetiapine, gabapentin, benzodiazepines for hot-flash-related insomnia), diphenhydramine stacks onto that existing load.

Falls are the leading cause of injury-related death in women over 65. The American Geriatrics Society Beers Criteria explicitly lists diphenhydramine as a drug to avoid in older adults precisely because of sedation and anticholinergic effects contributing to falls and delirium.

The Pharmacodynamic Overlap: Where the Real Risk Lives

No single published trial has studied the rosuvastatin-diphenhydramine combination in women specifically. This is an evidence gap worth naming. What we can do is map the overlapping pharmacodynamic effects:

| Effect | Rosuvastatin | Diphenhydramine | Combined concern | |---|---|---|---| | Sedation / CNS depression | None | High | Diphenhydramine alone; additive if other sedatives present | | Myopathy / muscle effects | Yes (dose-dependent) | None documented | No additive myopathy risk | | Hepatotoxicity | Rare | Rare | Monitor LFTs if both used long-term | | Urinary retention | None | Yes (anticholinergic) | Clinically relevant in women with pelvic floor dysfunction | | Cognitive impairment | Not established | Yes (acute and chronic) | Concern at perimenopause and post-menopause | | QTc prolongation | Not significant | Mild at high doses | Not a clinical concern at standard doses |

The framework above is designed to give prescribers and patients a structured way to assess pharmacodynamic overlap when no direct interaction trial exists. It is an approach the WomanRx editorial board recommends for pairs that have no hard contraindication but share patient-relevant adverse effect profiles.

Who Is Most at Risk: Life-Stage Breakdown

Reproductive Years (Ages 18-40)

If you are premenopausal and healthy, occasionally using diphenhydramine for sleep or allergy while on rosuvastatin is unlikely to cause serious harm. The main concern is sedation and performance impairment the next day. Use the lowest effective dose of diphenhydramine (25 mg rather than 50 mg) and take it only when you do not need to drive or operate equipment the following morning.

Rosuvastatin is generally started at a lower frequency in reproductive-age women because cardiovascular risk is lower before menopause, but women with familial hypercholesterolemia or PCOS-related dyslipidemia often start statin therapy in their 20s or 30s.

Women with PCOS have a substantially elevated cardiovascular risk profile. A meta-analysis in Human Reproduction Update found that PCOS is associated with significantly elevated triglycerides and LDL alongside reduced HDL, a lipid pattern that may warrant earlier statin use. If you have PCOS and are on rosuvastatin, the same interaction considerations apply, with the additional note that PCOS itself disrupts sleep architecture, making you more likely to reach for OTC sleep aids.

Trying to Conceive

Stop rosuvastatin before attempting conception. This is not negotiable. See the pregnancy section below. Diphenhydramine does not impair ovulation at standard doses, but its sedating properties may mask fever or other signals during an early pregnancy you do not yet know about.

Perimenopause (Approximately Ages 45-55)

This is where the combined pharmacodynamic risk is highest. Estrogen loss disrupts sleep in roughly 40-60% of perimenopausal women, which is exactly when many women start regularly using diphenhydramine as a sleep aid. Simultaneously, cardiovascular risk rises after menopause, so statin prescriptions increase in this decade.

Perimenopausal women also frequently carry multiple medications, including hormone therapy, antidepressants (often prescribed off-label for vasomotor symptoms), and sleep agents. Each anticholinergic drug you add increases cumulative burden. Diphenhydramine is a poor choice for chronic perimenopausal insomnia because it loses sleep-induction efficacy within three to five nights due to tolerance, while the anticholinergic side effects persist.

Post-Menopause

The Beers Criteria warning applies here most directly. If you are post-menopausal and on rosuvastatin for ASCVD prevention, diphenhydramine as a regular sleep aid is not recommended. Discuss doxylamine (slightly lower anticholinergic burden), low-dose melatonin, or CBT-I with your provider instead.

Pregnancy and Lactation Safety: Required Reading

Rosuvastatin is contraindicated in pregnancy. Stop it as soon as you know you are pregnant, and ideally before you try to conceive.

Rosuvastatin in Pregnancy

The rosuvastatin FDA prescribing information classifies the drug as contraindicated in pregnancy under the Pregnancy and Lactation Labeling Rule (PLLR). Cholesterol is necessary for fetal development, and HMG-CoA reductase inhibition during organogenesis carries theoretical teratogenic risk. Animal studies show skeletal malformations at doses equivalent to human clinical exposure. Human data are limited, but the ACOG clinical guidance and standard-of-care universally recommend stopping all statins before conception or immediately upon a positive pregnancy test.

If you are on rosuvastatin and not using reliable contraception, that is a conversation to have with your provider today. The standard recommendation is to use effective contraception throughout statin therapy if you are of reproductive potential.

Rosuvastatin in Lactation

Rosuvastatin transfers into human breast milk. The FDA label states that because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during rosuvastatin therapy. The theoretical concern is suppression of cholesterol synthesis in a rapidly developing infant brain.

Diphenhydramine in Pregnancy

Diphenhydramine has a long history of use in pregnancy, primarily as Unisom SleepTabs combined with vitamin B6 (doxylamine-pyridoxine, sold as Diclegis/Bonjesta) for nausea. The ACOG Practice Bulletin on Nausea and Vomiting of Pregnancy supports doxylamine use, which is structurally similar to diphenhydramine. Diphenhydramine itself is generally considered low-risk in the first and second trimesters based on large registry data, but use near term may cause neonatal withdrawal or respiratory depression. Avoid in the third trimester.

Diphenhydramine in Lactation

Diphenhydramine passes into breast milk. The LactMed database (NIH) notes that diphenhydramine may cause infant sedation, irritability, and poor feeding. First-generation antihistamines are generally not preferred in breastfeeding mothers; loratadine or cetirizine are better-studied and carry lower infant sedation risk.

Rosuvastatin Drug Interactions: The Broader Picture for Women

Since you are thinking about what goes with rosuvastatin, this is worth covering. The interactions that actually matter clinically are:

Interactions That Raise Rosuvastatin Levels (and Myopathy Risk)

• Cyclosporine: Contraindicated co-administration; increases rosuvastatin AUC approximately 7-fold.
• Gemfibrozil: Avoid; increases rosuvastatin AUC approximately 1.9-fold.
• Lopinavir/ritonavir: Relevant for women on antiretroviral therapy; increases rosuvastatin exposure approximately 2-fold.
• Atazanavir/ritonavir: Similarly increases exposure; dose cap of rosuvastatin 10 mg/day recommended.
• Niacin at doses >1 g/day: Additive myopathy risk independent of PK changes.

Myopathy and rhabdomyolysis risk from rosuvastatin is dose-dependent. Women are at higher baseline risk for statin-induced myopathy than men. A pharmacogenomics study published in The Lancet identified SLCO1B1 variants that sharply increase myopathy risk with simvastatin, and this transporter gene is relevant to rosuvastatin uptake as well.

Interactions That Are Commonly Feared but Not Clinically Significant

• Diphenhydramine: No significant PK interaction with rosuvastatin. Pharmacodynamic concern limited to sedation and anticholinergic burden (covered above).
• Magnesium/aluminum antacids: Take rosuvastatin 2 hours apart from antacids; antacid co-administration reduces rosuvastatin AUC by approximately 54%.
• Grapefruit juice: Minimal effect, unlike simvastatin or atorvastatin.

What to Use Instead of Diphenhydramine for Sleep on a Statin

If you are on rosuvastatin and struggling with sleep, diphenhydramine is one of the least suitable long-term options, and not primarily because of the statin. It is because diphenhydramine loses effectiveness rapidly, adds anticholinergic load, and impairs memory consolidation during REM sleep.

Better options by evidence level:

1. Cognitive behavioral therapy for insomnia (CBT-I): The American College of Physicians recommends CBT-I as first-line treatment for chronic insomnia in adults. It outperforms sleep medications at 12-month follow-up.
2. Melatonin 0.5-5 mg: Low anticholinergic burden, no interaction with rosuvastatin. Most effective for sleep-onset problems. Take 30-60 minutes before bed.
3. Doxylamine 25 mg: Slightly lower anticholinergic burden than diphenhydramine, also available OTC, but shares the same tolerance and cognitive concerns with regular use.
4. Low-dose melatonin receptor agonist (ramelteon 8 mg): Prescription, no anticholinergic effects, no interaction with rosuvastatin, FDA-approved for sleep-onset insomnia.
5. Address the root cause: In perimenopausal women, vasomotor symptoms (hot flashes, night sweats) are the primary driver of sleep disruption. Treating those with hormone therapy or evidence-based non-hormonal options often resolves insomnia without any sleep aid.

Who Should Be Most Careful Combining These Two Drugs

The combination is lowest risk for a woman who:

• Is under 50, premenopausal, in good cognitive health
• Takes diphenhydramine only occasionally (once or twice per month)
• Uses the lower 25 mg dose rather than 50 mg
• Is not on other sedating or anticholinergic drugs
• Plans a pregnancy and has discussed statin management with her provider

The combination warrants a direct provider conversation if you:

• Are perimenopausal or post-menopausal
• Take diphenhydramine three or more nights per week for sleep
• Are on other anticholinergic drugs (overactive bladder medications like oxybutynin, certain antidepressants like amitriptyline, scopolamine)
• Have a personal or family history of dementia or Alzheimer's disease
• Have pelvic floor dysfunction or urinary retention symptoms
• Are of reproductive age without reliable contraception while on rosuvastatin

Talking to Your Provider: What to Say

Most women do not think to mention OTC sleep or allergy medications to their prescriber. Here is what to bring up at your next visit:

"I take rosuvastatin for my cholesterol. I sometimes use diphenhydramine for sleep or allergies. Is there anything I should watch for? And what do you recommend instead for sleep?"

If you are perimenopausal and the sleep issues are primarily hot-flash-driven, ask specifically whether menopausal hormone therapy or a non-hormonal vasomotor symptom treatment like fezolinetant or the low-dose paroxetine (Brisdelle) could address the root cause, making the sleep aid unnecessary.